Autonomix Medical (NASDAQ:AMIX) is a clinical-stage medical device company specializing in the development and commercialization of innovative neurovascular therapies. The company focuses on minimally invasive solutions for the treatment of intracranial aneurysms, ischemic stroke and carotid artery disease. Autonomix’s product candidates are designed to enhance procedural efficiency and safety, leveraging proprietary engineering and biomaterials to deliver next-generation microcatheters, flow diverters and stent retrievers.
Founded in 2017 and headquartered in Irvine, California, Autonomix Medical emerged from collaborative research between interventional neuroradiologists and biomedical engineers. Since its inception, the company has advanced multiple product candidates through preclinical studies and regulatory milestones. Notably, the Neurolix stent retriever has received 510(k) clearance from the U.S. Food and Drug Administration, positioning Autonomix to address a significant market opportunity in acute ischemic stroke intervention.
Autonomix Medical currently serves healthcare providers across North America, with plans to secure CE marking for its pipeline products and expand distribution into Europe, Latin America and Asia-Pacific regions. The company has established strategic partnerships with leading neurointerventional centers to conduct clinical evaluations, generate real-world evidence and refine device design. This global approach aims to bring advanced neurovascular treatments to a broader patient population while supporting physician training and procedural adoption.
Under the leadership of CEO Paul Vrakas and a seasoned executive team, Autonomix Medical draws on extensive experience in medical device development, regulatory affairs and commercial strategy. The management team is supported by a Scientific Advisory Board composed of renowned neurovascular specialists, ensuring that product innovation aligns with evolving clinical practice. As Autonomix progresses through late-stage clinical testing, the company remains committed to improving patient outcomes and setting new standards in neurointerventional care.
